Online Program Home
  My Program

All Times EDT

* = applied session       ! = JSM meeting theme

Activity Details

342 * Wed, 8/5/2020, 10:00 AM - 2:00 PM Virtual
Clinical Trial Design: Statistical Methods and Applications in Oncology — Contributed Papers
Biopharmaceutical Section
Chair(s): Davis Gates, Merck
Application of Modulated Markov Models and Modulated Renewal Process for Analyzing Clinical Trial Data with Non-Proportional Hazard
Rianka Bhattacharya, Abbvie Inc.
A Generalized Framework of Optimal Two-Stage Designs for Exploratory Basket Trials
Fang Liu, Merck & Co., Inc; Xiaoqiang Wu, Florida State University; Iris Wu, Merck; Heng Zhou, Merck; Cong Chen, Merck and Company, Inc.
A Dose Escalation Design Considering Different Toxicity Onset Time Frames Using a Bayesian Piecewise Proportional Hazard Model
Hongjie Zhu, Beigene
The Optimal Randomization Ratio in Time-to-Event Trials Is Not 1:1
Godwin Yung, Genentech/Roche; Yi Liu, Nektar Therapeutics
Two-Stage Design for Single-Arm Phase II Cancer Clinical Trials with Two Alternative Primary Endpoints
Hui Gu, Boehringer Ingelheim; Yong Lin, Rutgers School of Public Health; Weichung Joe Shih, Rutgers School of Public Health; Yaqun Wang, Rutgers, School of Public Health, Dept. of Biostatistics; Kejian Liu, Sanofi